291. Hirschsprung disease, entire colon type Clinical trials / Disease details


Clinical trials : 12 Drugs : 24 - (DrugBank : 15) / Drug target gene : 0 - Drug target pathway : 0

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04904081
(ClinicalTrials.gov)
June 16, 202114/5/2021Feasibility of Use of Indocyanine Green in Pediatric Colorectal SurgeryThe Use of Indocyanine Green Angiography in Pediatric Colorectal Surgery: A Feasibility Randomized Controlled TrialHirschsprung Disease;Anorectal MalformationsDrug: Indocyanine greenLawson Health Research InstituteNULLRecruiting1 Month7 YearsAll12Phase 3Canada
2NCT04598841
(ClinicalTrials.gov)
January 1, 202118/10/2020Nutrition Support for Hirschsprung DiseaseA Multicentric Study on Pre-operative Nutritional Support for Hirschsprung's DiseaseNutrition Supporting;Hirschsprung Disease;Infants;Prospective StudyDietary Supplement: supplement nutritional supportingTongji HospitalNULLRecruiting0 Years5 YearsAll100N/AChina
3ChiCTR2000035860
2020-10-012020-08-18Artificial intelligence for pathological grading system of ganglion cells for intraoperative rapid biopsy in Hirschsprung diseaseArtificial intelligence for pathological grading system of ganglion cells for intraoperative rapid biopsy in Hirschsprung disease Hirschsprung diseaseGold Standard:The speciemens and sections will be reveiwed by three senior pediatric gastroenterology pathologists under the novel pathological grading system of ganglion cells in Hirschsprung disease, and the results is regarded as the gold standard.;Index test:Artificial intelligence assisted whole-section patholgic diagnosis system;Xinhua Hospital, Shanghai Jiaotong University School of MedicineNULLPending016BothTarget condition:138;Difficult condition:138China
4NCT04020939
(ClinicalTrials.gov)
March 16, 20202/7/2019The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery.The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery.Intestinal Atresia;Necrotizing Enterocolitis;Hirschsprung Disease;Gastroschisis;Intestinal Obstruction;Incarcerated Hernia;Intussusception;Malrotation;Volvulus;Meconium Ileus;Intestinal Perforation;TraumaDevice: SPY imaging;Drug: Indocyanine GreenSt. Justine's HospitalNULLCompletedN/A16 YearsAll35N/ACanada
5NCT03660176
(ClinicalTrials.gov)
January 2, 20194/9/2018Effects of Butyrate Enemas on Postoperative Intestinal Mobility Disorders in Hirschsprung's DiseaseEffects of Butyrate Enemas on Postoperative Intestinal Mobility Disorders in Hirschsprung'sHirschsprung's DiseaseDrug: butyrate enemas + routine management;Other: routine managementAssistance Publique Hopitaux De MarseilleNULLNot yet recruitingN/A17 YearsAll58Phase 3France
6NCT03593252
(ClinicalTrials.gov)
September 1, 201822/5/2018Bowel Preparation in Elective Pediatric Intestinal SurgeryMechanical Bowel Prep and Prophylactic Oral Antibiotic Use in Children: Implications for Intestinal Surgery ComplicationsColostomy Stoma;Ileostomy - Stoma;Jejunostomy Stoma;Hirschprung's Disease;NEC;Inflammatory Bowel Diseases;Meconium Ileus;Bowel ObstructionDrug: Senna;Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid;Drug: Erythromycin;Drug: Kanamycin;Drug: Cefazolin;Drug: Metronidazole;Other: Nil per osMcMaster UniversityNULLNot yet recruiting6 Months18 YearsAll48N/ANULL
7JPRN-UMIN000024993
2016/12/0115/12/2016Study for efficacy of usage of enteral nutrient with immuno-balance modulation action in perioperative management of pediatric patientsStudy for efficacy of usage of enteral nutrient with immuno-balance modulation action in perioperative management of pediatric patients - Efficacy in usage of enteral nutrient with immuno-balance modulation action Hirschsprung's disease, Atresia ani, Congenital biliary dilatation, GERDIn the control group, the following enteral nutrient will be administered (breast milk or artificial milk for infants, Racol for infants).
Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day.
In contrast, immunomodulatory nutrition is administered in the test group.
Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day.

The study period is from December 1, 2016 to March 31, 2018.
University of Tsukuba HospitalNULLPending6months-old48months-oldMale and Female10Not applicableJapan
8NCT02343562
(ClinicalTrials.gov)
October 20149/1/2015Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated EnterocolitisProbiotics for Prophylaxis of Postoperative Hirschsprungs Associated EnterocolitisHirschsprung DiseaseDietary Supplement: Probiotics;Dietary Supplement: PlaceboCairo UniversityNULLUnknown status6 Months12 YearsAll40Phase 4Egypt
9NCT02350088
(ClinicalTrials.gov)
January 201417/1/2015Fast-track Surgery in the Treatment of Hirschsprung's DiseaseFast-track Surgery in the Treatment of Hirschsprung's DiseaseSurgeryDrug: probiotics;Drug: placeboTongji HospitalChildren's Hospital BostonRecruiting1 Year18 YearsBoth100N/AChina
10NCT02216994
(ClinicalTrials.gov)
January 20136/8/2014A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective StudyEfficacy and Accuracy of a New Diagnostic Scoring System to Differentiate Hirschsprung Disease From Hirschsprung Disease Allied Disorders in the Patients With Suspected Intestinal Dysganglinosis: a Prospective StudyHirschsprung DiseaseDrug: high dose lactulose;Behavioral: conservative treatment;Drug: paraffin oilTongji HospitalJiangxi Provincial Children's HospitalRecruitingN/A3 YearsBoth80N/AChina
11NCT01934959
(ClinicalTrials.gov)
January 200821/8/2013A Trial on Probiotics in Preventing Hirschsprung's Disease Associated EntercolitisA Prospective Multicenter Randomized Controlled Trial on Probiotics in Preventing Hirschsprung's Disease Associated EntercolitisProbiotics;Hirschsprung's Disease Associated EnterocolitisDrug: BificoTongji HospitalAnhui Provincial HospitalCompleted1 Month13 YearsBoth60Phase 0NULL
12NCT00630838
(ClinicalTrials.gov)
September 200628/2/2008Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)Hirschsprung DiseaseDrug: VSL#3;Drug: PlaceboUniversity of MichiganNULLCompleted1 Month12 MonthsAll62Phase 2United States